300122:SZSEChongqing Zhifei Biological Products Co., Ltd. Class A Analysis

Chongqing Zhifei Biological is trading at CNY 15.04, far below its DCF fair value of CNY 52.56, implying a potential upside of ~45% based on the model. The stock sits just above the computed support of CNY 14.57 and below resistance at CNY 16.76, with the 20‑day SMA (15.34) under the 50‑day SMA (15.57), signaling a short‑term bearish bias. However, the MACD histogram is positive (0.025) and the MACD signal turned bullish, while the RSI of 44 suggests the price is not yet oversold. Volume is increasing, indicating growing market participation, but volatility remains high at 37.7% over the past 30 days and beta is low (0.5), reflecting modest systematic risk. Fundamental metrics are mixed: the forward PE of 9.96 is well below the industry average of 26.7, yet trailing earnings are negative, margins are deeply in the red, and debt‑to‑equity is high at 72%. A recent news item notes a shortfall in Gardasil demand in China, prompting Merck and Zhifei to renegotiate their partnership, which could pressure revenue growth further. Despite a generous dividend yield of 5.22%, the payout ratio is effectively zero, raising questions about dividend sustainability. Overall, the stock appears dramatically undervalued on a valuation basis but carries significant operational and regulatory headwinds.
Investors should weigh the attractive yield and upside potential against the company's loss‑making profile, high leverage, and sector‑specific regulatory risks. The technical picture suggests caution in the near term, while the long‑run thesis hinges on a turnaround in vaccine sales and improved cash generation.